AstraZeneca battles pediatrician group over preemie drug guidelines

28-07-2014 WSJ Pharmalot BlogComments (0)

AstraZeneca

Once again, there is controversy over an expensive drug for premature babies. At issue are new American Academy of Pediatrics guidelines that recommend scaling back usage of a drug called Synagis, which costs several thousand dollars and is sold by AstraZeneca, because evidence shows the medicine benefits few children other than very young preemies.

Read more on WSJ Pharmalot Blog

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top